Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression


Kocaturk B., Tieken C., Vreeken D., Unlu B., Engels C. C., de Kruijf E. M., ...Daha Fazla

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, cilt.13, sa.9, ss.1683-1693, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 9
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/jth.13049
  • Dergi Adı: JOURNAL OF THROMBOSIS AND HAEMOSTASIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1683-1693
  • Anahtar Kelimeler: blood coagulation, cell movement, cell proliferation, integrin beta1, tumors, FACTOR EXPRESSION, TUMOR-GROWTH, CELLS, PROLIFERATION, ANGIOGENESIS, ACTIVATION, COAGULATION, TAMOXIFEN, THERAPY, TARGET
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BackgroundProcoagulant full-length tissue factor (flTF) and its minimally coagulant alternatively spliced isoform (asTF), promote breast cancer (BrCa) progression via different mechanisms. We previously showed that flTF and asTF are expressed by BrCa cells, resulting in autoregulation in a cancer milieu. BrCa cells often express hormone receptors such as the estrogen receptor (ER), leading to the formation of hormone-regulated cell populations.